News and Announcements
Imugene’s Cancer Vacine Recieves Grant Notice from Canadian Patent Office
- Published August 18, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Imugene Limited (ASX:IMU) has recently announced news it has received notice that the Canadian Patent Office has issued a Grant Notice for the Company’s cancer vaccine HER-Vaxx.
KEY TAKEAWAYS:
- Canadian Patent Office has issued Grant Notice for Imugene’s patent application protecting its cancer vaccine “HER-Vax”
- Patent will protect specific cancer vaccine formulations of commercial interest
HER-Vaxx works by targeting the same receptor as Herceptin and Perjeta, two of the leading drugs on the market, with annual sales of US$8.2 billion. The mechanism of action for HER-Vaxx may help generate improved efficacy over existing treatments and at a lower cost.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
